Strategic Partnerships Novalix is actively pursuing partnerships with AI-enabled hit discovery via OpenBench and antibody discovery collaborations with iBody, signaling a growth vector in alliance-driven revenue and expanded service offerings that can be targeted for co-selling and joint projects.

Biophysics Expansion Recent integration of switchSENSE technology with Bruker heliX biosensors expands Novalix’s biophysics capabilities, presenting opportunities to upsell advanced binding and kinetic analysis services to existing clients and attract biotech firms needing real-time interaction profiling.

Geographic Growth Strategic hiring to fortify France, Benelux, UK, Nordics, Austria, and Germany indicates a deliberate expansion in Western Europe, suggesting sales opportunities with regional biotechs and pharma companies seeking local collaboration and faster project kickoffs.

Leadership & Advisory Addition of senior advisor and business development leadership strengthens market credibility and deal generation capability, enabling targeted outreach to larger pharma and biotech firms seeking experienced drug discovery partners.

Internal Enablement Launch of internal programs like Better Science Talks demonstrates a culture of scientific excellence and knowledge sharing, which can be leveraged in client communications to illustrate a strong, collaborative partner mindset and differentiated scientific rigor.